Newsroom
Sorted by: Latest
-
Campbell's Reports Second Quarter Fiscal 2026 Results
CAMDEN, N.J.--(BUSINESS WIRE)--The Campbell's Company (NASDAQ:CPB) today reported results for its second quarter fiscal 2026 ended February 1, 2026. Unless otherwise stated, all comparisons are to the same period of fiscal 2025. CEO Comments: "Our core Meals & Beverages portfolio delivered in-market consumption growth in the second quarter, highlighted by the Rao’s brand surpassing $1 billion in trailing twelve-month net sales. Overall results, however, fell short of our expectations due to...
-
BKV Corporation Announces Pricing of Public Offering of Common Stock
DENVER--(BUSINESS WIRE)--BKV Corporation (“BKV” or the “Company”) (NYSE: BKV) today announced the pricing of its underwritten public offering of 9,692,089 shares of its common stock (the “Offering”), which includes 5,550,000 shares being offered by the Company and 4,142,089 shares being offered by Bedrock Energy Partners, LLC (the “selling stockholder”). The total estimated gross proceeds of the Offering, before deducting the underwriter’s discounts and commissions and estimated Offering fees a...
-
TIAA-CREF UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Teachers Insurance and Annuity Association of America/TIAA-CREF Investment Management, LLC/Teachers Advisors, LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle compan...
-
Veristat Expands Regulatory and Clinical Services to Chinese Drug and Device Companies Seeking Efficient Way to Enter European Markets
SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--Veristat, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced expanded regulatory and clinical trial services to international pharmaceutical and medical device companies seeking a streamlined path into European, including the United Kingdom and Switzerland, plus Australian, Canadian, and U.S. markets. Particularly, Veristat has helped many Chinese companies – including Hansoh Pharma and CStone Pharmaceut...
-
Sprinklr Announces Fourth Quarter and Full Year Fiscal 2026 Results
NEW YORK--(BUSINESS WIRE)--Sprinklr Announces Fourth Quarter and Full Year Fiscal 2026 Results...
-
Verituity Advances Confidence-Based Verification at the Point of Payout
MCLEAN, Va.--(BUSINESS WIRE)--Verituity announces an expansion of its verification framework with confidence-based Payment Method Verification at the point of payout....
-
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has received two Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent applications relating to the Company’s PBGENE-HBV program. The first Notice of Allowance relates to U.S. Patent Application No. 19/347,136, tit...
-
Predictable Power: StandardAero Selected by Robinson Helicopter Company as Preferred MRO Provider for R66 Rolls-Royce RR300 Engines
SCOTTSDALE, Ariz. & TORRANCE, Calif.--(BUSINESS WIRE)--StandardAero (NYSE: SARO), a leading independent pure-play provider of aerospace engine aftermarket services including engine maintenance, repair and overhaul (MRO) and engine component repair, has been selected by U.S. helicopter OEM, Robinson Helicopter Company, to support their global fleet of R66 helicopters powered by the Rolls-Royce RR300 engine. This relationship will provide R66 helicopter owners and operators with a Robinson-recomm...
-
Smith Douglas Homes Reports Fourth Quarter and Full Year 2025 Results
ATLANTA--(BUSINESS WIRE)--Smith Douglas Homes Corp. (NYSE: SDHC) (“Smith Douglas” or the “Company”) today announced results for the fourth quarter and year ended December 31, 2025. Q4 2025 Results as compared to Q4 2024: Home closings decreased 7% to 780 Home closing revenue decreased 9% to $260.4 million Home closing gross margin of 19.9% compared to 25.5% Net new home orders decreased 7% to 532 Pre-tax income of $16.9 million compared to $30.0 million Earnings of $0.39 per diluted share Full...
-
Swarm Aero Announces $35M Series A Financing Led by Two Sigma Ventures and Silent Ventures
OXNARD, Calif.--(BUSINESS WIRE)--Swarm Aero announces $35M Series A financing to accelerate the development and deployment of the company’s large UAV and swarm software....